FDA Timelines Put Patient Access and Evidence in Focus
Amylyx is set to present detailed avexitide trial results as Savara faces a delayed FDA decision, while a medication recall and Medicare enrollment rules carry practical stakes for patients.
Amylyx is set to present detailed avexitide trial results as Savara faces a delayed FDA decision, while a medication recall and Medicare enrollment rules carry practical stakes for patients.
Democratic control of Congress could intensify oversight of the Trump administration’s emissions agenda, while Suncor’s results show the cash still generated by oil production.
This week’s reporting points to U.S. political uncertainty and Bitcoin ETF withdrawals, but identifies no new Bitcoin protocol upgrade or cryptographic advance.
Pharmaceutical shares fell after a new U.S. drug-price probe, but the available reporting does not identify its scope or show how it may affect patients.
Jeff Bezos has cited Austin as an example of housing policy that can encourage construction, but available reports do not establish which measures produced what results.
A federal push for a disputed New York gas pipeline and Nigeria’s review of gas licences and fuel reserves put energy security’s costs and benefits in focus.
The FTC’s Second Request extends its review of the proposed MiMedx-Sanara MedTech merger, while a senior Justice Department official says antitrust prosecutors remain ready to litigate.
California’s new transit-oriented housing law and a crowded slate of state ballot measures put zoning, development and affordability policy before voters and local governments.
Recent headlines offer no verified figures on wages, hiring or workforce participation, while reported AI safety incidents raise questions about oversight—not proven job losses.